Chengdu-based medical device firm Burning Rock Biotech Ltd (NASDAQ: BNR) announced the launch of a ground-breaking interventional validation study focused on the application of its early cancer test, OverC, in detecting various cancer types in asymptomatic patients. The PREVENT (Prospective multi-canceR Early-detection and interVENTional) study will enroll 12,500 individuals to evaluate the performance of the OverC test in detecting six cancer types that together account for 50% of China’s total cancer incidence and 62% of mortality: lung, liver, colorectal, esophageal, pancreatic and ovarian cancers.
Study Details
Led by West China Hospital of Sichuan University, the study aligns with China’s current health policy priority to improve the rate of early cancer detection. The aim is to enhance early cancer screening and diagnosis, which could lead to adjustments in treatment paradigms, ultimately improving the survival times and quality of life of cancer patients.-Fineline Info & Tech
